Medicus 2014;23(1):31-46
46
Doc. dr. sc. Suzana Mimica Matanović, dr. med.
specijalist kliničke farmakologije s toksikologijom
KBC Osijek
Huttlerova 4
31000 Osijek
tel.: 031-511-108
e-mail:
18. 11. 2013.
17. 2. 2014.
ADRESA ZA DOPISIVANJE:
PRIMLJENO/RECEIVED:
PRIHVAĆENO/ACCEPTED:
32. Babu KS, Salvi SS. Aspirin and asthma. Chest 2000;118:1470–6.
33. Rang HP, Dale MM, Ritter JM, Moore PK. Farmakologija (hrvat-
sko izdanje). Golden marketing, Zagreb, 2006.
34. Rainsford KD. Anti-inflammatory drugs in the 21st century. Sub-
cell Biochem 2007;42:3–27.
35. Bäckström M, Hägg S, Mjörndal T, Dahlqvist R. Utilization
pattern of metamizole in northern Sweden and risk estimates of
agranulocytosis. Pharmacoepidemiol Drug Saf 2002;11:239–45.
36. Hedenmalm K, Spigset O. Agranulocytosis and other blood dys-
crasias associated with dipyrone (metamizole). Eur J Clin Phar-
macol 2002;58:265–74.
37. Ibáñez L, Vidal X, Ballarín E, Laporte JR. Agranulocytosis
associated with dipyrone (metamizol). Eur J Clin Pharmacol
2005;60:821–9.
38. Katzung i sur. Temeljna i klinička farmakologija. 11. (hrvatsko)
izdanje. Medicinska naklada, Zagreb, 2011.
39. European Medicines Agency. Restrictions on use of codeine for
pain relief in children – CMDh endorses PRAC recommendati-
on. Dostupno na:
-
l=pages/news_and_events/news/2013/06/news_detail_001829.
jsp&mid=WC0b01ac058004d5c1. Datum pristupa: 15.11.2013.
40. Labianca R, Sarzi-Puttini P, Zuccaro SM i sur. Adverse effects
associated with non-opioid and opioid treatment in patients
with chronic pain. Clin Drug Investig 2012;32 Suppl 1:53–63.
41. Leppert W. The role of opioid receptor antagonists in the tre-
atment of opioid-induced constipation: a review. Adv Ther
2010;27:714–30.
42. Rauck RL. Treatment of opioid-induced constipation: focus on
the peripheral μ-opioid receptor antagonist methylnaltrexone.
Drugs 2013;73:1297–306.
43. Heiskanen T, Mätzke S, Haakana S i sur. Transdermal fentanyl in
cachectic cancer patients. Pain 2009;144:218–22.
44.Wolff RF, Aune D, Truyers C i sur. Systematic review of efficacy and
safety of buprenorphine versus fentanyl or morphine in patients with
chronicmoderate to severe pain. CurrMedResOpin 2012;28:833–45.
45. Tassinari D, Sartori S, Tamburini E i sur. Adverse effects of tran-
sdermal opiates treating moderate-severe cancer pain in compa-
rison to long-acting morphine: a meta-analysis and systematic
review of the literature. J Palliat Med 2008;11:492–501.
46. Hrvatska agencija za lijekove i medicinske proizvode. Pismo lje-
karnicima o povećanom nadzoru nad izdavanjem lijekova koji
sadrže djelatnu tvar kodein zbog opasnosti razvoja ovisnosti.
Dostupno na:
.
pdf. Datum pristupa: 17.2.2014.
47. Bockbrader HN, Wesche D, Miller R i sur. A comparison of the
pharmacokinetics and pharmacodynamics of pregabalin and ga-
bapentin. Clin Pharmacokinet 2010;49:661–9.
48. Brunton L, Chabner B, Knollman B. Goodman and Gilman’s
The Pharmacological Basis of Therapeutics, Twelfth Edition.
McGraw-Hill Professional 2010.
MimicaMatanović S.
